210.80
+8.93%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sun Pharma Advanced Research Co
Its shares trade on NSE under the ticker SPARC.NS. It has been listed since 18 July 2007. In the fiscal year to 31 March 2026, it reported revenue of ₹18.79bn and net income of ₹15.53bn. At that date it held total assets of ₹21.71bn and shareholders' equity of ₹13.39bn.
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The firm develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. The company has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. The company has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jul 2007
- Employees
- 407
- Website
- sparc.life ↗
Leadership
Pay as last reported
- Mr. Dilip ShanghviNon-Executive Chairman of the Board, since 2006₹390,000
- Mr. Anilkumar RaghavanChief Executive Officer₹56.7m
- Mr. Anup RathiChief Financial Officer
- Ms. Kajal DamaniaCompliance Officer, Company Secretary₹2.0m
- Dr. Thennati RajamannarNon-Executive Director, since 2007₹300,000
- Ms. Vidhi ShanghviNon-Executive Director₹480,000
- Smt. Bhavna DoshiNon-Executive Independent Director₹690,000
- Dr. Ferzaan EngineerNon-Executive Independent Director₹600,000
- Mr. Venkateswarlu JastiNon-Executive Independent Director
- Dr. Robert SpiegelNon-Executive Independent Director₹600,000
- Ms. Rekha WarriarNon-Executive Independent Director
- Mr. Jaydeep IssraniInvestor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 36
- Social
- 40
- Governance
- 56
- Women in the workforce
- 34%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Mumbai, Maharashtra with 407 employees.
- Engages in R&D of pharmaceuticals for unmet medical needs in oncology, neurodegeneration, and immunology.
- Develops New Chemical Entities, New Biological Entities, and reformulated products including SCC-138, SCO-088, SCO-120, and SCD-044.
Weaknesses
- IPO date is 2007-07-18, indicating a long-standing company with potential legacy systems.
- Website is https://www.sparc.life/ which may not be widely recognized.
- Limited information on commercial success of products like Xelpros and PDP-716.
Opportunities
- Development of products for unmet medical needs in oncology, neurodegeneration, and immunology.
- Expansion of Novel Drug Delivery Systems such as Wrap Matrix Technology, Lipexelle technology, and TearAct Technology.
- Partnerships for commercialization of products like Xelpros in the United States.
Threats
- Untrusted source description may lead to inaccurate information about the company's products and technologies.
- Potential competition in the pharmaceutical R&D sector for unmet medical needs.
- Dependence on partners for commercialization of products like Xelpros.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.